Stratification of type 2 diabetes based on routine clinical markers
(2018) In Diabetes Research and Clinical Practice 141. p.275-283- Abstract
AIMS: We hypothesized that patients with dysregulated type 2 diabetes may be stratified based on routine clinical markers.
METHODS: In this retrospective cohort study, diabetes related clinical measures including age at onset, diabetes duration, HbA1c, BMI, HOMA2-β, HOMA2-IR and GAD65 autoantibodies, were used for sub-grouping patients by K-means clustering and for adjusting. Probability of diabetes complications (95% confidence interval), were calculated using logistic regression.
RESULTS: Based on baseline data from patients with type 2 diabetes (n = 2290), the cluster analysis suggested up to five sub-groups. These were primarily characterized by autoimmune β-cell failure (3%), insulin resistance with short disease... (More)
AIMS: We hypothesized that patients with dysregulated type 2 diabetes may be stratified based on routine clinical markers.
METHODS: In this retrospective cohort study, diabetes related clinical measures including age at onset, diabetes duration, HbA1c, BMI, HOMA2-β, HOMA2-IR and GAD65 autoantibodies, were used for sub-grouping patients by K-means clustering and for adjusting. Probability of diabetes complications (95% confidence interval), were calculated using logistic regression.
RESULTS: Based on baseline data from patients with type 2 diabetes (n = 2290), the cluster analysis suggested up to five sub-groups. These were primarily characterized by autoimmune β-cell failure (3%), insulin resistance with short disease duration (21%), non-autoimmune β-cell failure (22%), insulin resistance with long disease duration (32%), and presence of metabolic syndrome (22%), respectively. Retinopathy was more common in the sub-group characterized by non-autoimmune β-cell failure (52% (47.7-56.8)) compared to other sub-groups (22% (20.1-24.1)), adj. p < 0.001. The prevalence of cardiovascular disease, nephropathy and neuropathy also differed between sub-groups, but significance was lost after adjustment.
CONCLUSIONS: Patients with type 2 diabetes cluster into clinically relevant sub-groups based on routine clinical markers. The prevalence of diabetes complications seems to be sub-group specific. Our data suggests the need for a tailored strategy for the treatment of type 2 diabetes.
(Less)
- author
- Safai, Narges ; Ali, Ashfaq LU ; Rossing, Peter and Ridderstråle, Martin LU
- publishing date
- 2018-07
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Biomarkers/blood, Cohort Studies, Diabetes Mellitus, Type 2/drug therapy, Humans, Retrospective Studies
- in
- Diabetes Research and Clinical Practice
- volume
- 141
- pages
- 9 pages
- publisher
- Elsevier
- external identifiers
-
- scopus:85047653146
- pmid:29782936
- ISSN
- 1872-8227
- DOI
- 10.1016/j.diabres.2018.05.014
- language
- English
- LU publication?
- no
- id
- d27abb81-1eb3-4558-a1d8-0d99c77c2736
- date added to LUP
- 2019-01-22 14:09:09
- date last changed
- 2024-09-03 10:53:04
@article{d27abb81-1eb3-4558-a1d8-0d99c77c2736, abstract = {{<p>AIMS: We hypothesized that patients with dysregulated type 2 diabetes may be stratified based on routine clinical markers.</p><p>METHODS: In this retrospective cohort study, diabetes related clinical measures including age at onset, diabetes duration, HbA1c, BMI, HOMA2-β, HOMA2-IR and GAD65 autoantibodies, were used for sub-grouping patients by K-means clustering and for adjusting. Probability of diabetes complications (95% confidence interval), were calculated using logistic regression.</p><p>RESULTS: Based on baseline data from patients with type 2 diabetes (n = 2290), the cluster analysis suggested up to five sub-groups. These were primarily characterized by autoimmune β-cell failure (3%), insulin resistance with short disease duration (21%), non-autoimmune β-cell failure (22%), insulin resistance with long disease duration (32%), and presence of metabolic syndrome (22%), respectively. Retinopathy was more common in the sub-group characterized by non-autoimmune β-cell failure (52% (47.7-56.8)) compared to other sub-groups (22% (20.1-24.1)), adj. p < 0.001. The prevalence of cardiovascular disease, nephropathy and neuropathy also differed between sub-groups, but significance was lost after adjustment.</p><p>CONCLUSIONS: Patients with type 2 diabetes cluster into clinically relevant sub-groups based on routine clinical markers. The prevalence of diabetes complications seems to be sub-group specific. Our data suggests the need for a tailored strategy for the treatment of type 2 diabetes.</p>}}, author = {{Safai, Narges and Ali, Ashfaq and Rossing, Peter and Ridderstråle, Martin}}, issn = {{1872-8227}}, keywords = {{Biomarkers/blood; Cohort Studies; Diabetes Mellitus, Type 2/drug therapy; Humans; Retrospective Studies}}, language = {{eng}}, pages = {{275--283}}, publisher = {{Elsevier}}, series = {{Diabetes Research and Clinical Practice}}, title = {{Stratification of type 2 diabetes based on routine clinical markers}}, url = {{http://dx.doi.org/10.1016/j.diabres.2018.05.014}}, doi = {{10.1016/j.diabres.2018.05.014}}, volume = {{141}}, year = {{2018}}, }